The FDA has taken two notable actions affecting drug access and development plans: it partially paused Biohaven’s epilepsy program on safety questions and expanded Bayer’s Hyrnuo lung cancer label into the first-line setting. In parallel, an earlier Hyrnuo accelerated approval for previously treated patients enabled the broader move. For Biohaven, regulators placed a partial clinical hold on BHV-7000 shortly after the company attracted additional deal attention, citing requests for more information tied to preclinical safety. Biohaven said it would provide requested materials while the study enrollment is affected. Separately, Bayer’s Hyrnuo (sevabertinib) received FDA accelerated approval expansion to treat adults with locally advanced or metastatic nonsquamous HER2-mutant NSCLC—moving from post–systemic therapy into first-line use. Together, the updates underscore how oncology labeling gains can arrive alongside development delays in neurology, with downstream implications for trial timelines, investor expectations, and competitive positioning in biomarker-defined populations.